Celeste Durnwald1, Lisa Mele2, Mark B Landon3, Michael W Varner4, Brian M Casey5, Uma M Reddy6, Ronald J Wapner7, Dwight J Rouse8, Alan T N Tita9, John M Thorp10, Edward K Chien11, George R Saade12, Alan M Peaceman13, Sean C Blackwell14. 1. Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania. 2. George Washington University Biostatistics Center, Washington, District of Columbia. 3. Department of Obstetrics and Gynecology, The Ohio State University, Columbus, Ohio. 4. Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, Utah. 5. Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas. 6. Eunice Kennedy Shriver National Institute of Child Health and Human Development (U.M.R.), Bethesda, Maryland. 7. Department of Obstetrics and Gynecology, Columbia University, New York, New York. 8. Department of Obstetrics and Gynecology, Brown University, Providence, Rhode Island. 9. Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama. 10. Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina. 11. Department of Obstetrics and Gynecology, MetroHealth Medical Center - Case Western Reserve University, Cleveland, Ohio. 12. Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas. 13. Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois. 14. Department of Obstetrics and Gynecology, University of Texas Health Science Center at Houston-Children's Memorial Hermann Hospital, Houston, Texas.
Abstract
OBJECTIVE: We sought to determine if there is an association between fibroblast growth factor 21 (FGF21) levels and a history of gestational diabetes mellitus (GDM) in women with and without metabolic dysfunction, defined as a diagnosis of metabolic syndrome or type 2 diabetes (T2DM), 5 to 10 years following participation in a multiple cohort GDM study. STUDY DESIGN: At 5 to 10 years after index pregnancy, women underwent a follow-up visit and were categorized as having no metabolic syndrome, metabolic syndrome, or T2DM. FGF21 levels were compared between women who did and did not have a history of GDM using multivariable linear regression. RESULTS: Among 1,889 women, 950 underwent follow-up and 796 had plasma samples analyzed (413 GDM and 383 non-GDM). Total 30.7% of women had been diagnosed with T2DM or metabolic syndrome. Overall, there was no difference in median FGF21 levels in pg/mL between the prior GDM and non-GDM groups (p = 0.12), and the lack of association was observed across all three metabolic categories at follow-up (p for interaction = 0.70). CONCLUSION: There was no association between FGF21 levels and prior history of mild GDM in women with and without metabolic dysfunction 5 to 10 years after the index pregnancy (ClinicalTrials.gov number, NCT00069576, original trial). Thieme. All rights reserved.
OBJECTIVE: We sought to determine if there is an association between fibroblast growth factor 21 (FGF21) levels and a history of gestational diabetes mellitus (GDM) in women with and without metabolic dysfunction, defined as a diagnosis of metabolic syndrome or type 2 diabetes (T2DM), 5 to 10 years following participation in a multiple cohort GDM study. STUDY DESIGN: At 5 to 10 years after index pregnancy, women underwent a follow-up visit and were categorized as having no metabolic syndrome, metabolic syndrome, or T2DM. FGF21 levels were compared between women who did and did not have a history of GDM using multivariable linear regression. RESULTS: Among 1,889 women, 950 underwent follow-up and 796 had plasma samples analyzed (413 GDM and 383 non-GDM). Total 30.7% of women had been diagnosed with T2DM or metabolic syndrome. Overall, there was no difference in median FGF21 levels in pg/mL between the prior GDM and non-GDM groups (p = 0.12), and the lack of association was observed across all three metabolic categories at follow-up (p for interaction = 0.70). CONCLUSION: There was no association between FGF21 levels and prior history of mild GDM in women with and without metabolic dysfunction 5 to 10 years after the index pregnancy (ClinicalTrials.gov number, NCT00069576, original trial). Thieme. All rights reserved.